Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 12, 2009
JNCI Journal of the National Cancer Institute 2009 101(10):704-706; doi:10.1093/jnci/djp135
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/10/704    most recent
djp135v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Finkelstein, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finkelstein, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Federal Task Force Seeks Standards for Immunotherapy Biomarker Studies

Joel B. Finkelstein

The first 10% of the full text of this article appears below.

Researchers could be learning more from clinical trials of cancer immunotherapy, according to organizers of a workshop who are looking for novel biomarkers that accurately predict response to these treatments.

"The clinical trials of cancer immunotherapies haven’t been terribly successful. The problem so far is that the strategies that have been tried, if not successful clinically, you don’t learn that much from them," said Peter Lee, M.D., an associate professor of hematology at Stanford University's School of Medicine and a member of a new Taskforce on Immunotherapy Biomarkers, which is organizing the workshop.

Jointly sponsored by the U.S. Food and Drug Administration and the International Society for the Biological Therapy of Cancer, the task force's goal is to build on existing consensus within the cancer community to facilitate the discovery and validation of new biomarkers. Agreeing on common research . . . [Full Text of this Article]

The Problems

Possible Solutions

Mandating Strategy?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?